S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
S&P 500   3,351.28 (+0.06%)
DOW   27,433.48 (+0.17%)
QQQ   271.47 (-1.15%)
AAPL   444.45 (-2.45%)
MSFT   212.48 (-1.79%)
FB   268.44 (+1.19%)
GOOGL   1,498.37 (-0.44%)
AMZN   3,167.46 (-1.78%)
NVDA   447.98 (-1.20%)
CGC   16.63 (-5.08%)
BABA   252.10 (-5.11%)
TSLA   1,452.71 (-2.48%)
MU   48.75 (+0.10%)
GE   6.40 (+1.11%)
AMD   84.85 (-2.15%)
T   30.02 (+0.60%)
F   6.86 (-1.01%)
ACB   10.27 (-0.39%)
GILD   69.35 (+0.78%)
NFLX   494.73 (-2.82%)
DIS   129.93 (-0.68%)
BAC   26.11 (+2.51%)
BA   170.02 (-1.27%)
Log in

NASDAQ:ADXSAdvaxis Stock Price, Forecast & News

$0.55
-0.02 (-3.44 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.53
Now: $0.55▼
$0.57
50-Day Range
$0.53
MA: $0.58▼
$0.64
52-Week Range
$0.21
Now: $0.55▼
$1.48
Volume1.09 million shs
Average Volume3.03 million shs
Market Capitalization$33.88 million
P/E RatioN/A
Dividend YieldN/A
Beta3.53
Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Read More
Advaxis logo

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.61 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
Previous Symbol
CUSIPN/A
CIK1100397
Webwww.advaxis.com
Phone609-452-9813

Debt

Debt-to-Equity Ratio0.16
Current Ratio7.52
Quick Ratio7.52

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20.88 million
Price / Sales1.62
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.30 per share
Price / Book0.24

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-16,610,000.00
Net Margins-13,144.62%
Return on Equity-82.46%
Return on Assets-69.06%

Miscellaneous

Employees58
Outstanding Shares61,608,000
Market Cap$33.88 million
Next Earnings Date9/14/2020 (Estimated)
OptionableOptionable
$0.55
-0.02 (-3.44 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Advaxis (NASDAQ:ADXS) Frequently Asked Questions

How has Advaxis' stock been impacted by COVID-19 (Coronavirus)?

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADXS stock has decreased by 17.5% and is now trading at $0.55.
View which stocks have been most impacted by Coronavirus.

When is Advaxis' next earnings date?

Advaxis is scheduled to release its next quarterly earnings announcement on Monday, September 14th 2020.
View our earnings forecast for Advaxis.

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) announced its quarterly earnings results on Thursday, June, 11th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.15) by $0.05. The biotechnology company had revenue of $0.25 million for the quarter. Advaxis had a negative net margin of 13,144.62% and a negative return on equity of 82.46%.
View Advaxis' earnings history.

Has Advaxis been receiving favorable news coverage?

News articles about ADXS stock have trended very positive recently, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Advaxis earned a media sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Advaxis.

Who are some of Advaxis' key competitors?

Some companies that are related to Advaxis include KITOV PHARMA LT/S (KTOV), OASMIA PHARMACE/ADR (OASM), Obseva (OBSV), Inflarx (IFRX), Lumos Pharma (LUMO), Checkpoint Therapeutics (CKPT), Mallinckrodt (MNK), Xeris Pharmaceuticals (XERS), Axovant Gene Therapies (AXGT), Corvus Pharmaceuticals (CRVS), SUMMIT THERAPEU/S (SMMT), Sierra Oncology (SRRA), Catabasis Pharmaceuticals (CATB), PhaseBio Pharmaceuticals (PHAS) and Evolus (EOLS).
View all competitors.

What other stocks do shareholders of Advaxis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Anavex Life Sciences (AVXL), Celgene (CELG), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), Novavax (NVAX) and Opko Health (OPK).

Who are Advaxis' key executives?

Advaxis' management team includes the following people:
  • Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
  • Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
  • Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
  • Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Who are Advaxis' major shareholders?

Advaxis' stock is owned by many different institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.27%). Company insiders that own Advaxis stock include Robert Petit and Roni Appel.
View institutional ownership trends for Advaxis.

Which major investors are buying Advaxis stock?

ADXS stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Advaxis.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.55.

How big of a company is Advaxis?

Advaxis has a market capitalization of $33.88 million and generates $20.88 million in revenue each year. Advaxis employs 58 workers across the globe.

What is Advaxis' official website?

The official website for Advaxis is www.advaxis.com.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

This page was last updated on 8/7/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.